Table 1.
Characteristics of Deliveries to Women With and Without Human Immunodeficiency Virus
| Characteristics | Deliveries to Women With HIV in IMPAACT P1025a (n = 2868) (Column Percentage) | Deliveries to Women Without HIV in CSLb (n = 211 910) (Column Percentage) | P c |
|---|---|---|---|
| Maternal age at delivery, mean (SD), years | 28.2 (6.1) | 27.8 (6.2) | .002 |
| Parity | <.001 | ||
| 0 | 493 (17) | 84 924 (40) | |
| 1 or more | 2375 (83) | 126 986 (60) | |
| Delivery year | <.001 | ||
| 2002 | 149 (5) | 16 952 (8) | |
| 2003 | 219 (8) | 15 522 (7) | |
| 2004 | 281 (10) | 58 428 (28) | |
| 2005 | 328 (11) | 66 683 (31) | |
| 2006 | 246 (9) | 53 977 (25) | |
| 2007 | 294 (10) | 290 (<1) | |
| 2009 | 326 (11) | … | |
| 2010 | 289 (10) | … | |
| 2011 | 288 (10) | … | |
| 2012 | 300 (10) | … | |
| 2013 | 148 (5) | … | |
| Maternal race | <.001 | ||
| Black | 1671 (58) | 46 374 (23) | |
| White | 259 (9) | 103 654 (51) | |
| Latina | 857 (30) | 38 406 (19) | |
| Other | 81 (3) | 14 218 (7) | |
| US Census region | <.001 | ||
| Northeast | 685 (24) | 55 645 (26) | |
| West | 719 (25) | 68 630 (32) | |
| Midwest | 308 (11) | 18 928 (9) | |
| South, including Puerto Rico | 1156 (41) | 68 707 (32) | |
| Mode of delivery | <.001 | ||
| Vaginal | 1365 (48) | 151 079 (71) | |
| Cesarean | 1467 (52) | 60 830 (29) | |
| Gestational age at delivery, mean (SD), weeks | 38.2 (2.2) | 38.2 (2.5) | <.001 |
| History of preterm birth | 414 (14) | 15 372 (7) | <.001 |
| Multiple gestation | 51 (2) | 4746 (2) | .09 |
| Among women with HIV in IMPAACT P1025 | |||
| Entry into prenatal care | … | … | |
| ≥14 weeks | 985 (34) | ||
| <14 weeks | 1874 (66) | ||
| Viral load at delivery | … | … | |
| ≥400 copies/mL | 438 (16) | ||
| <400 copies/mL | 2384 (84) | ||
| ART guideline period | … | … | |
| 2002–2008 | 1517 (53) | ||
| 2009–2013 | 1351 (47) | ||
| ART regimen | … | … | |
| ≥3 NRTIs | 338 (12) | ||
| ≥3 ARVs with NRTI | 196 (7) | ||
| ≥3 ARVs with PI | 2334 (81) |
Data are presented as n (%) unless otherwise indicated. Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral drug; CSL, Consortium on Safe Labor; HIV, human immunodeficiency virus; IMPAACT P1025, International Maternal Pediatric Adolescent AIDS Clinical Trials Protocol P1025; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SD, standard deviation.
aMissing data in IMPAACT P1025 for the following covariates: gestational age at delivery (n = 8), history of preterm birth (n = 7), entry into prenatal care (n = 9), RNA viral load at delivery (n = 46), mode of delivery (n = 36),
bMissing data in CSL for the following covariates: age at delivery (n = 321), delivery year (n = 58), race (n = 9258), history of preterm birth (n = 5374), and mode of delivery (n = 1).
cA statistically significant P value <.05 may reflect a difference due to large sample size.